TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29773947
Drug: BFF MDI
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BFF MDI 320/9.6 μg
Study: 28635557
Drug: Intradermal split-virus
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal split-virus TIV
Study: 25668581
Drug: Erhuangfang (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erhuangfang (treatment group, n=50)
Study: 16651569
Drug: Periarticular intraoperative
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periarticular intraoperative injection containing ropivacaine, ketorolac, epimorphine, and epinephrine
Study: 8949810
Drug: Droperidol added
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Droperidol added to morphine infusion
Study: 6784982
Drug: Naloxone (long-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (long-term infusion)
Study: 6784982
Drug: High-dose DAMME
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose DAMME infusion
Study: 28903864
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate and vilanterol (100 μg or 200 μg with 25 μg vilanterol)
Study: 19410392
Drug: DHEA 50mg
Normalized name: Natrol Mood & Stress DHEA 50mg Tablet
DrugBank: Prasterone sulfate (DB05804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 50mg daily
Study: 9508013
Drug: Milk diet
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk diet (360 mL)
Study: 9508013
Drug: Juice diet
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Juice diet (540 mL)
Study: 8001541
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (4 x 5 g.day‐1 for 5 days)
Study: 29637845
Drug: Circuit only
Normalized name: BREATHING CIRCUIT W/MOUTHPIECE,STANDARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circuit only weekly performances
Study: 25531413
Drug: Intrauterine injection
Normalized name: ETHIODIZED OIL 480 mg in 1 mL INTRAUTERINE INJECTION [LIPIODOL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrauterine injection of 500 IU hCG before embryo transfer
Study: 24060300
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of 4 mg of triamcinolone acetonide (TA) plus grid laser photocoagulation (GLP)
Study: 11929419
Drug: Nasal steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal steroids
Study: 18445106
Drug: Ethanol high
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol high concentration (breathalyzer = 0.100 g/dl)
Study: 18445106
Drug: Ethanol low
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol low concentration (breathalyzer = 0.040 g/dl)
Study: 11020003
Drug: Interferon alpha2b
Normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha2b plus ribavirin (1000 mg/day)
Study: 11020003
Drug: Double dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dosage of alpha‐interferon (6 million units tiw)
Study: 9093599
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of anti-TNF alpha Fab, 30 min before penicillin in 20 patients
Study: 3153213
Drug: Regimen A
Normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A (five different drug associations including VM26 and IDMTX in a sequential schedule)
Study: 3153213
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (classical Spiers schedule for the first year, followed by milder treatment)
Study: 3153213
Drug: Patients relapsing
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients relapsing after 12 months from suspension of treatment in first complete remission
Study: 3153213
Drug: Patients relapsing
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients relapsing within the first year off therapy
Study: 30209050
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose folic acid (4.0 mg/day, four 1.0 mg oral tablets) from 8 weeks of gestation to week 16 until delivery.
Study: 22520140
Drug: Oral pentavalent
Normalized name: rotavirus vacc, live oral pentavalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pentavalent rotavirus vaccine (PRV), RotaTeq, 3 doses at approximately 6, 10, and 14 weeks of age
Study: 22520140
Drug: Oral pentavalent
Normalized name: rotavirus vacc, live oral pentavalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pentavalent rotavirus vaccine (PRV), RotaTeq
Study: 20118150
Drug: Triple group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple group (cilostazol 100 mg twice daily + clopidogrel 75 mg daily)
Study: 20118150
Drug: High maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: High maintenance dose (MD) group (clopidogrel 150 mg daily)
Study: 20118150
Drug: Standard group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard group (clopidogrel 75 mg daily)
Study: 20118150
Drug: High maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: High maintenance dose (MD) group
Study: 18198640
Drug: Shenqi Fuzheng
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenqi Fuzheng Injection (SFI), intravenously dripped once daily, starting 3 days before radiotherapy to 1 week after the end of it.
Study: 18198640
Drug: Shenqi Fuzheng
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenqi Fuzheng Injection (SFI).
Study: 16305269
Drug: Clinic treatment
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinic treatment group (supervised exercise, individualized manual therapy, home exercise program)
Study: 16305269
Drug: Clinic treatment
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinic treatment group
Study: 12218500
Drug: Lidocaine patch
Normalized name: LIDOCAINE 40 mg TOPICAL PATCH [Lidocaine Patch]
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine patch 5% (LP)
Study: 25781654
Drug: BCAA infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BCAA infusion (N = 5) during insulin infusion at 40 mU/m2/min
Study: 25781654
Drug: BCAA infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BCAA infusion (N = 4) during insulin infusion at 80 mU/m2/min
Study: 22030938
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac sodium 1% gel (DSG), applied 4 g to 1 or both knees 4 times daily for 9 to 12 months.
Study: 22030938
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac sodium 1% gel (DSG).
Study: 18390970
Drug: Adjuvant cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant cyclophosphamide, doxorubicin, and fluorouracil (CAF) chemotherapy
Study: 18390970
Drug: High-dose CAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose CAF chemotherapy
Study: 1620456
Drug: IgIv 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgIv 0.2 g/kg on day 0, day 2, day 5, day 12
Study: 30231894
Drug: Training via
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training via locally made educational videos on low-cost Android tablets
Study: 24152086
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone furoate (200 μg for 7 days, then 800 μg for 7 days from a dry powder inhaler)
Study: 24152086
Drug: Intravenous fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluticasone furoate (250 μg infusion)
Study: 24152086
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone furoate (200 μg)
Study: 24152086
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone furoate (200 μg and 800 μg)
Study: 20655662
Drug: Standard treatment+cognitive‐behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment+cognitive‐behavioral skills training (STD+CBT)
Study: 20655662
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (STD)
Study: 16217588
Drug: Raloxifene 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 120 mg/day and 150 mg/day (RLX120/150)
Study: 14733645
Drug: Cisplatin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (50 mg/m2) plus Gemcitabine (1000 mg/m2) plus Vinorelbine (25 mg/m2) (PGV)
Study: 14733645
Drug: Cisplatin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (100 mg/m2) plus Gemcitabine (1000 mg/m2) (PG)
Study: 14733645
Drug: Cisplatin (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (120 mg/m2) plus Vinorelbine (30 mg/m2/week) (PV)
Study: 14621718
Drug: Immunosuppressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive treatment groups
Study: 3902413
Drug: Topical ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ampicillin (1 g in each surgical wound)
Study: 3902413
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotics (ampicillin 1 g X 3 and metronidazole 0.5 g X 3)
Study: 31881991
Drug: Guideline-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-based treatment as usual (TAU)
Study: 26291594
Drug: High-dose intracoronary
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intracoronary N-acetylcysteine (100 mg/kg bolus, followed by 10 mg·kg⁻¹·h⁻¹ for 12 hours)
Study: 31451273
Drug: Dextrose solution
Normalized name: Dextrose solution
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose solution (control)
Study: 26291594
Drug: High-dose intracoronary
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intracoronary N-acetylcysteine
Study: 12631373
Drug: Icodextrin 7.5%
Normalized name: ICODEXTRIN 7.5% SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icodextrin 7.5% solution
Study: 12631373
Drug: Standard glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard glucose solutions
Study: 10759661
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride (TCl, 20 mg twice daily)
Study: 8838434
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg caroverine
Study: 8838434
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg caroverine
Study: 8838434
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg caroverine
Study: 1349494
Drug: Cetirizine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (2 x 10 mg daily for 3 days)
Study: 2416297
Drug: Desipramine hydrochloride
Normalized name: Desipramine Hydrochloride
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desipramine hydrochloride (norepinephrine uptake inhibitor)
Study: 2416297
Drug: Zimeldine hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Zimelidine (DB04832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimeldine hydrochloride (serotonin uptake inhibitor)
Study: 2416297
Drug: Clorgyline (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clorgyline (selective monoamine oxidase type A inhibitor)
Study: 27926472
Drug: Sweetened beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sweetened beverage intake >2 servings daily (6% of participants)
Study: 27926472
Drug: Each 200
Normalized name: danicopan
DrugBank: Danicopan (DB15401)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 200 mL daily serving of sweetened beverages
Study: 25721356
Drug: Docetaxel plus
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel plus Prednisone plus Low-Dose Cyclophosphamide
Study: 9026175
Drug: Estrogen therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen therapy (transdermal estrogen patch)
Study: 1672137
Drug: Psoralen +
Normalized name: Psoralen
DrugBank: Psoralen (DB18665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psoralen + UVA (PUVA) therapy
Study: 6752871
Drug: Pirprofen (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirprofen (1200 mg, 400 mg t.i.d.)
Study: 6752871
Drug: Indomethacin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (150 mg, 50 mg t.i.d.)
Study: 31903802
Drug: PM2.5 exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: PM2.5 exposure (10 µg/m3 increase in 1-month mean)
Study: 28350181
Drug: Catheter oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheter oxygen group with Hb ≤ 70 g/L
Study: 28350181
Drug: Catheter oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheter oxygen group with 71 g/L ≤ Hb ≤ 90 g/L
Study: 28350181
Drug: Ventilator-assisted breathing
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventilator-assisted breathing group with 71 g/L ≤ Hb ≤ 90 g/L
Study: 28350181
Drug: Ventilator-assisted breathing
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventilator-assisted breathing group with Hb ≥ 91 g/L
Study: 28350181
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of 71 g/L ≤ Hb ≤ 90 g/L subgroups
Study: 21684428
Drug: Pandemic H1N1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pandemic H1N1 live attenuated influenza vaccine (LAIV)
Study: 18443134
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (fish oil; Omegaven 10%; 0.15 - 0.2 g/kg/d)
Study: 12544374
Drug: Intranasal AVP
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal AVP (2 x 20 IU) for 10 weeks
Study: 11043125
Drug: Both operative
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both operative and non-operative treatment
Study: 11043125
Drug: Retrospective studies
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Retrospective studies (both operative and conservative therapy)
Study: 12056098
Drug: Dexrazoxane at
Normalized name: Dexrazoxane
DrugBank: Dexrazoxane (DB00380)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexrazoxane at 500 mg/m2 commencing at the seventh cycle of treatment
Study: 27423044
Drug: Roflumilast 0.5
Normalized name: roflumilast 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast 0.5 mg
Study: 27423044
Drug: Roflumilast 0.25
Normalized name: roflumilast 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast 0.25 mg
Study: 27423044
Drug: Roflumilast 0.375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast 0.375 mg
Study: 12683708
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level energy laser therapy (LLLT) with Gallium Arsenide laser irradiation at 890 nm
Study: 11531635
Drug: 800 mcg
Normalized name: Biotin 800 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mcg misoprostol per rectum
Study: 3254763
Drug: Noradrenaline infusion
Normalized name: noradrenaline hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenaline infusion (0‐54 ng min‐1 kg‐1) for 15 min per dose
Study: 31356558
Drug: Oral nano
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nano vitamin D (60,000 IU/d for 8 days)
Study: 31356558
Drug: Oral nano
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nano vitamin D
Study: 28198572
Drug: Ultrasound-guided rectus
Normalized name: Sus scrofa rectum preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided rectus sheath block with 0.2 ml·kg‐1 of 0.375% ropivacaine per side
Study: 28198572
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic infiltration with 0.2 ml·kg‐1 of 0.75% ropivacaine
Study: 26258177
Drug: Nanohybrid composite
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nanohybrid composite (E&Ra/nanoC) - G-aenial with three-step etch-and-rinse adhesive system (Optibond FL)
Study: 23931889
Drug: HA330 hemoperfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA330 hemoperfusion treatment (N=25)
Study: 23931889
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (N=21)
Study: 21757141
Drug: Dan-Chi-Liu-Wei combination
Normalized name: Bai Liu Bark
DrugBank: Salix alba bark (DB14274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dan-Chi-Liu-Wei combination (DCLWC)
Study: 16881780
Drug: Drug use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug use (for women)
Study: 15572490
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 10 mg ephedrine followed by a continuous infusion for 60 minutes of 20 mg ephedrine
Study: 11357168
Drug: 30 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/d of recombinant human interleukin-1 receptor antagonist (IL-1ra)
Study: 11357168
Drug: 75 mg/d
Normalized name: Lyllana 0.075 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg/d of recombinant human interleukin-1 receptor antagonist (IL-1ra)
Study: 11357168
Drug: 150 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/d of recombinant human interleukin-1 receptor antagonist (IL-1ra)
Study: 7525422
Drug: Free fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free fluid volume > 20 ml or free fluid colour > grade 5 on the Leeds chart
Study: 30349139
Drug: Monosodium L-glutamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monosodium L-glutamate (MSG) 0.9 g/dose, thrice daily
Study: 30349139
Drug: NaCl 0.26
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0.26 g/dose, thrice daily (Control group)
Study: 29549464
Drug: Allopurinol 5
Normalized name: allopurinol 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 5 mg/kg/day for 4 months
Study: 14725500
Drug: 2 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 minutes video of a dentist explaining what an injection will feel like and proposing hand raising as a signal mechanism
Study: 11864504
Drug: Bivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent inactivated vaccine
Study: 6124906
Drug: Fazadinium (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fazadinium (1 mg/kg)
Study: 26475166
Drug: 0.5% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% levobupivacaine 15 mL
Study: 26475166
Drug: 0.5% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% levobupivacaine 15 mL with 1:200,000 epinephrine
Study: 26475166
Drug: 0.75% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% ropivacaine 15 mL
Study: 23018435
Drug: Control therapy
Normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control therapy (control arm, n = 14)
Study: 20386508
Drug: Exogenous arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Exogenous arginine vasopressin infusion (AVP) at doses of 0.033 IU/min and 0.067 IU/min
Study: 20386508
Drug: Decrease in
Normalized name: Titanium Dioxide 7.2 g in 100 mL / Zinc Oxide 4 g in 100 mL TOPICAL LIQUID [Decree Daily Shield Broad Spectrum SPF 30 Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decrease in copeptin levels during AVP therapy
Study: 12404707
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg of scopolamine (SP)
Study: 12404707
Drug: 1.2 mg
Normalized name: RNA 1.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mg of scopolamine (SP)
Study: 12569761
Drug: Larger dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larger dose of ribavirin
Study: 12569761
Drug: Routine therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine therapeutic dose of ribavirin (Control)
Study: 7804972
Drug: Octreotide 100
Normalized name: 1 ML octreotide 100 MCG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 100 micrograms three times per day and tamoxifen 10 mg twice daily
Study: 2230868
Drug: High-dose megestrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose megestrol acetate (MA), 800 mg/d
Study: 2230868
Drug: Standard-dose megestrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose megestrol acetate (MA), 160 mg/d
Study: 20186887
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition (no treatment, 10 minutes)
Study: 8858279
Drug: Midazolam 10
Normalized name: midazolam 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 10 mg with grapefruit juice (GraMid)
Study: 8858279
Drug: Midazolam 10
Normalized name: midazolam 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 10 mg with water (Mid)
Study: 8858279
Drug: Triazolam 0.25
Normalized name: triazolam 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam 0.25 mg with grapefruit juice (GraTrz)
Study: 8858279
Drug: Midazolam 10
Normalized name: midazolam 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 10 mg with erythromycin (EryMid)
Study: 8858279
Drug: Midazolam 10
Normalized name: midazolam 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 10 mg alone
Study: 28816693
Drug: Multiple-frequency matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-frequency matching therapy
Study: 28816693
Drug: Single-frequency matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-frequency matching therapy